Sandy Cove Advisors LLC Has $840,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Sandy Cove Advisors LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,359 shares of the company’s stock after selling 73 shares during the period. Sandy Cove Advisors LLC’s holdings in Johnson & Johnson were worth $840,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Hibernia Wealth Partners LLC bought a new position in Johnson & Johnson during the 3rd quarter worth approximately $27,000. FNY Investment Advisers LLC bought a new position in Johnson & Johnson during the 3rd quarter worth approximately $37,000. Tower View Wealth Management LLC raised its holdings in Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares during the last quarter. Creative Capital Management Investments LLC raised its holdings in Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after purchasing an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC bought a new position in Johnson & Johnson during the 2nd quarter worth approximately $48,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on JNJ shares. Morgan Stanley lowered their price target on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. UBS Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Wells Fargo & Company lowered shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $170.00 to $163.00 in a research note on Wednesday, December 13th. Finally, Raymond James lifted their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $177.31.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $157.96 on Thursday. The firm has a market capitalization of $380.65 billion, a PE ratio of 11.44, a price-to-earnings-growth ratio of 2.62 and a beta of 0.53. The firm has a fifty day simple moving average of $158.76 and a two-hundred day simple moving average of $156.69. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 12 month low of $144.95 and a 12 month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. The business had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. Johnson & Johnson’s quarterly revenue was down 9.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.35 EPS. Analysts forecast that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th were issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 3.01%. The ex-dividend date of this dividend was Friday, February 16th. Johnson & Johnson’s dividend payout ratio is 34.47%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.